HLB Pharm (047920) is on the rise as both the KOSPI and KOSDAQ indexes climb together. Buying interest is also flowing into HLB group stocks, drawing investors' attention.

As of 11:05 a.m. on the 30th, HLB Pharm is trading at 12,490 won, up 460 won (3.82%) from the previous trading day. At the same time, the KOSPI is at 6,908.12, up 37.31 points (0.54%), while the KOSDAQ has risen 11.4 points (1.34%) to 861.20. Notably, the KOSDAQ, where HLB Pharm is listed, is showing a relatively sharp gain.

Group stocks are also strong across the board. In particular, HLB Life Sciences has surged more than 14% at the same time, standing out among group stocks with its notable upward momentum.

Recently, HLB group stocks have shown high volatility since news broke that Replikto (ralpaglutinib), a bile duct cancer treatment developed by U.S. subsidiary Eleva Therapeutics, received product approval from the U.S. Food and Drug Administration (FDA). On the 28th, numerous group stocks, including HLB, HLB Pharm, and HLB Life Sciences, rose sharply.

[※ This article is for investment reference purposes only and does not constitute a recommendation to invest in any specific stock.]